Identifying miRNA‑mRNA regulation network of major depressive disorder in ovarian cancer patients

Wu,Chengjiang; Zhao,Yangjing; Liu,Yuefang; Yang,Xinxin; Yan,Meina; Min,Yujiao; Pan,Zihui; Qiu,Shali; Xia,Sheng; Yu,Jun; Yang,Peifang; Wan,Bing; Shao,Qixiang

doi:10.3892/ol.2018.9243

Identifying miRNA‑mRNA regulation network of major depressive disorder in ovarian cancer patients

Authors:
- Chengjiang Wu
- Yangjing Zhao
- Yuefang Liu
- Xinxin Yang
- Meina Yan
- Yujiao Min
- Zihui Pan
- Shali Qiu
- Sheng Xia
- Jun Yu
- Peifang Yang
- Bing Wan
- Qixiang Shao
View Affiliations

Affiliations: Department of Respiratory Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu 210002, P.R. China, Department of Immunology, Key Laboratory for Laboratory Medicine of Jiangsu, Jiangsu University Medical School, Zhenjiang, Jiangsu 212013, P.R. China, Department of Gynecology and Obstetrics, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China
Published online on: July 31, 2018 https://doi.org/10.3892/ol.2018.9243
Pages: 5375-5382
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Major depression disorder (MDD) has become increasingly common in patients with ovarian cancer, which complicates the treatment course. The microRNA (miRNA)‑mRNA regulation network may help elucidate the potential mechanism of MDD in ovarian cancer. The differentially expressed microRNAs (DEmiRs) and mRNAs (DEmRNAs) were therefore identified from the GSE61741, GSE58105 and GSE9116 ovarian cancer datasets using GEO2R. The target genes of the DEmiRs were then obtained using the TargetScan, microRNAorg, microT‑CDS, miRDB and miRTarBase prediction tools. The DAVID program was used to identify the KEGG pathways of target genes, and the core genes of major depressive disorder (MDD) were identified using the Kaplan‑Meier Plotter for ovarian cancer. A total of 5 DEmiRs (miR‑23b‑3p, miR‑33b‑3p, miR‑1265, miR‑933 and miR‑629‑5p) were obtained from GSE61741 and GSE58105. The target genes of these DEmiRs were enriched in pathways that were considered high risk for developing MDD in ovarian cancer. A total of 11 risk genes were selected from these pathways as the core genes in the miRNA‑mRNA network of MDD in ovarian cancer, and eventually identified the following 12 miRNA‑mRNAs pairs: miR‑629‑5p‑FGF1, miR‑629‑5p‑AKT3, miR‑629‑5p‑MAGI2, miR‑933‑BDNF, miR‑933‑MEF2A, miR‑23b‑3p‑TJP1, miR‑23b‑3p‑JMJD1, miR‑23b‑3p‑APAF1, miR‑23b‑3p‑CAB39, miR‑1265‑CDKN1B, miR‑33b‑3p‑CDKN1B, and miR‑33b‑3p‑F2R. These results may provide novel insights into the mechanisms of developing MDD in ovarian cancer patients.

View Figures

View References

1	Massic MJ: Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr. 57–71. 2004. View Article : Google Scholar : PubMed/NCBI
2	Bailey RK, Geyen DJ, Scott-Gurnell K, Hipolito MM, Bailey TA and Beal JM: Understanding and treating depression among cancer patients. Int J Gynecol Cancer. 15:203–208. 2005. View Article : Google Scholar : PubMed/NCBI
3	Bodurka-Bevers D, Basen-engquist K, Carmack CL, Fitzgerald MA, Wolf JK, de Moor C and Gershenson DM: Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol. 78:302–308. 2000. View Article : Google Scholar : PubMed/NCBI
4	Price MA, Butow PN, Costa DS, King MT, Aldridge LJ, Fardell JE, DeFazio A and Webb PM: Australian Ovarian Cancer Study Group; Australian Ovarian Cancer Study Group Quality of Life Study Investigators: Prevalence and predictors of anxiety and depression in women with invasive ovarian cancer and their caregivers. Med J Aust. 193 5 Suppl:S52–S57. 2010.PubMed/NCBI
5	Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S and Hu H: Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 554:317–322. 2018. View Article : Google Scholar : PubMed/NCBI
6	Cui Y, Yang Y, Ni Z, Dong Y, Cai G, Foncelle A, Ma S, Sang K, Tang S, Li Y, et al: Astroglial Kir4.1 in the lateral habenula drives neuronal bursts in depression. Nature. 554:323–327. 2018. View Article : Google Scholar : PubMed/NCBI
7	Lovejoy NC and Matties M: Pharmacokinetics and pharmacodynamics of mood-altering drugs in patients with cancer. Cancer Nurs. 19:407–418. 1996. View Article : Google Scholar : PubMed/NCBI
8	Dwivedi Y, Rizavi HS, Roberts RC, Conley RC, Tamminga CA and Pandey GN: Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J Neurochem. 77:916–928. 2001. View Article : Google Scholar : PubMed/NCBI
9	Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unification of biology. The gene ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
10	Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30. 2000. View Article : Google Scholar : PubMed/NCBI
11	Huang DW, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protoc. 4:44–57. 2009. View Article : Google Scholar
12	da Huang W, Sherman BT and Lempicki RA: Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
13	Gyorffy B, Lánczky A and Szállási Z: Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data of 1287 patients. Endocr Relat Cancer. 19:197–208. 2012. View Article : Google Scholar : PubMed/NCBI
14	Plattner F, Hayashi K, Hernández A, Benavides DR, Tassin TC, Tan C, Day J, Fina MW, Yuen EY, Yan Z, et al: The role of ventral striatal cAMP signaling in stress-induced behaviors. Nat Neurosci. 18:1094–1100. 2015. View Article : Google Scholar : PubMed/NCBI
15	Wong KK: Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat Anticancer Drug Discov. 4:28–35. 2009. View Article : Google Scholar : PubMed/NCBI
16	Dwivedi Y, Rizavi HS, Roberts RC, Conley RC, Tamminga CA and Pandey GN: Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J Neurochem. 77:916–928. 2001. View Article : Google Scholar : PubMed/NCBI
17	Taliaz D, Stall N, Dar DE and Zangen A: Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis. Mol Psychiatry. 15:80–92. 2010. View Article : Google Scholar : PubMed/NCBI
18	Ding L, Zhang C, Masood A, Li J, Sun J, Nadeem A, Zhang HT, O'Donnell JM and Xu Y: Protective effects of phosphodiesterase 2 inhibitor on depression- and anxiety-like behaviors: involvement of antioxidant and anti-apoptotic mechanism. Behav Brain Res. 268:150–158. 2014. View Article : Google Scholar : PubMed/NCBI
19	Wu M, Chen Y, Jiang L, Li Y, Lan T, Wang Y and Qian H: Type II cGMP-dependent protein kinase inhibits epidermal growth factor-induced phosphatidylinositol-3-kinase/Akt signal transduction in gastric cancer cell. Oncol Lett. 6:1723–1728. 2013. View Article : Google Scholar : PubMed/NCBI
20	Tao Y, Gu YJ, Cao ZH, Bian XJ, Lan T, Sang JR, Jiang L, Wang Y, Qian H and Chen YC: Endogenous cGMP-dependent protein kinase reverses EGF-induced MAPK/ERK signal transduction through phosphorylation of VASP at Ser239. Oncol Lett. 4:1104–1108. 2012. View Article : Google Scholar : PubMed/NCBI
21	Karami-Tehrani F, Fallahian F and Atri M: Expression of cGMP-dependent protein kinase, PKGIα, PKGIβ, and PKGII in malignant and benign breast tumors. Tumor Biol. 33:1927–1932. 2012. View Article : Google Scholar
22	Li H, Zeng J and Shen K: PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. Arch Gynecol Obstet. 290:1067–1078. 2014. View Article : Google Scholar : PubMed/NCBI
23	Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P and Schroeter ML: BDNF as a biomarker for successful treatment of mood disorders: A systematic & quantitative meta-analysis. J Affect Disord. 174:432–440. 2015. View Article : Google Scholar : PubMed/NCBI
24	Bachis A, Mallei A, Cruz MI, Wellstein A and Mocchetti I: Chronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neurons. Neropharmacology. 55:1114–1120. 2008. View Article : Google Scholar
25	Jiao J, Zhao X, Liang Y, Tang D and Pan C: FGF1-FGFR1 axis promotes tongue squamous cell carcinoma (TSCC) metastasis through epithelial-mesenchymal transition (EMT). Biochem Biophys Res Commun. 466:327–332. 2015. View Article : Google Scholar : PubMed/NCBI
26	Renaud F, Desset S, Oliver L, Gimenez-Gallego G, Van Obberghen E, Courtois Y and Laurent M: The neurotrophic activity of fibroblast growth factor 1 (FGF1) depends on endogenous FGF1 expression and is independent of the mitogen-activated kinase cascade pathway. J Biol Chem. 271:2801–2811. 1996. View Article : Google Scholar : PubMed/NCBI
27	Cohen MM Jr: The AKT genes and their roles in various disorders. Am J Med Genet A. 161A:2931–2937. 2013. View Article : Google Scholar : PubMed/NCBI
28	Madhunapantula SV and Robertson GP: Targeting protein kinase-b3 (akt3) signaling in melanoma. Expert Opin Ther Targets. 21:273–290. 2017. View Article : Google Scholar : PubMed/NCBI
29	Yeganeh PN, Richardson C, Bahrani-Mostafavi Z, Tait DL and Mostafavi MT: Dysregulation of AKT3 along with a small panel of mRNAs stratifies high-grade serous ovarian cancer from both normal epithelia and benign tumor tissue. Genes Cancer. 8:784–798. 2017.PubMed/NCBI
30	Poduri A, Evrony GD, Cai X, Elhosary PC, Beroukhim R, Lehtinen MK, Hills LB, Heinzen EL, Hill A, Hill RS, et al: Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron. 74:41–48. 2012. View Article : Google Scholar : PubMed/NCBI
31	Hirao K, Hata Y, Ide N, Takeuchi M, Irie M, Yao I, Deguchi M, Toyoda A, Sudhof TC and Takai Y: A novel multiple PDZ domain-containing molecule interacting with N-methyl-D-aspartate receptors and neuronal cell adhesion proteins. J Biol Chem. 273:21105–21110. 1998. View Article : Google Scholar : PubMed/NCBI
32	Hirao K, Hata Y, Yao I, Deguchi M, Kawabe H, Mizoguchi A and Takai Y: Three isoforms of synaptic scaffolding molecule and their characterization. Multimerization between the isoforms and their interaction with N-methyl-D-aspartate receptors and SAP90/PSD-95-associated protein. J Bol Chem. 275:2966–2972. 2000. View Article : Google Scholar
33	Hu Y, Li Z, Guo L, Wang L, Zhang L, Cai X, Zhao H and Zha X: MAGI-2 Inhibits cell migration and proliferation via PTEN in human hepatocarcinoma cells. Arch Biochem Biophys. 467:1–9. 2007. View Article : Google Scholar : PubMed/NCBI